معرفی
Herman Sintim is the Grace-Rupley Professor of Chemical Biology in the Department of Chemistry and Biochemistry at the University of Notre Dame, where he also serves as the Associate Director of the Harper Cancer Research Institute. He has previously held faculty positions at Purdue University and the University of Maryland at College Park, progressing from Assistant to Full Professor. His research is highly interdisciplinary, bridging organic chemistry, chemical biology, and drug discovery.
Research Interests: Dr. Sintim's research focuses on understanding and modulating cyclic dinucleotide signaling pathways in both bacteria and mammalian immune systems. His lab explores the roles of molecules like c-di-GMP, c-di-AMP, and cGAMP in biofilm formation, virulence, and immune activation, particularly via the STING pathway. A major thrust is the development of small molecule probes and therapeutics targeting these pathways for use in cancer immunotherapy and as novel antibiotics. Additionally, his group pioneers the synthesis of new kinase inhibitors using multi-component reactions to combat drug resistance in cancer, targeting kinases such as FLT3, CDKs, and RET.
The recent publications of the Sintim group reflect a strong trend in designing novel chemotypes for both STING modulation (agonists and antagonists) and kinase inhibition, with an emphasis on oral bioavailability and efficacy in animal models. These works span chemical synthesis, biochemical evaluation, and translational applications in oncology and immunology.
Scientific Awards:
- Lafayette Lions Club Cancer Research Award (2022)
- Sigma Xi Distinguished Lecturer (2015)
- Camille Dreyfus Teacher-Scholar Award (2011)
- Allen Angerio Award for Excellence in Faculty Mentorship (2010)
- Kavli Fellow (2009)
- NSF CAREER Award (2008)
- Roche First Prize, Switzerland (2002)
- First Innocentive Awardee (2001)
- Pfizer UK PhD Prize (2001)
- ORS Fellowship, University of Oxford (2000)
- Pathfinder Scholarship, University College London (1996)
Advising and Grants: While specific students are not listed, Dr. Sintim has a well-established record of mentoring, recognized by awards such as the Allen Angerio Award. He has secured major funding through grants like the NSF CAREER Award and has advanced drug discovery projects to the level of co-founding KinaRx LLC, indicating strong translational grant and entrepreneurial success. His leadership as Associate Director of a major cancer research institute further underscores his role in guiding research teams and collaborative science.
Labs and Teams: The Sintim Research Group at Notre Dame operates at the intersection of synthetic organic chemistry and biological signaling, with active projects in cancer, inflammation, and antibiotic discovery. The lab employs integrated computational and experimental workflows and collaborates widely, as seen in multi-institutional publications involving researchers in pharmacology, oncology, and immunology.
